Skip NavigationSkip to Content
Return Return to Search Results

Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells

  1. Author:
    Bu, Wei
    Joyce, M. Gordon
    Banh, Dalton V.
    Aguilar, Fiona
    Tariq, Zeshan
    Yap, Moh Lan
    Tsujimura, Yusuke
    Gillespie, Rebecca A.
    Tsybovsky,Yaroslav
    Andrews, Sarah F.
    Narpala, Sandeep R.
    McDermott, Adrian B.
    Rossmann, Michael G.
    Yasutomi, Yasuhiro
    Nabel, Gary J.
    Kanekiyo, Masaru
    Cohen, Jeffrey I.

  2. Author Address

    NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA.Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.Univ Tunku Abdul Rahman, Fac Sci, Dept Biol Sci, Kampar 31900, Perak, Malaysia.Natl Inst Biomed Innovat Hlth & Nutr, Tsukuba Primate Res Ctr, Lab Immunoregulat & Vaccine Res, Tsukuba, Ibaraki 3050843, Japan.Leidos Biomed Res Inc, Electron Microscopy Lab, Adv Res Technol Facil, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.Sanofi, Cambridge, MA 02139 USA.
    1. Year: 2019
    2. Date: May 21
    3. Epub Date: 2019 04 09
  2. Journal: Immunity
  3. CELL PRESS,
    1. 50
    2. 5
    3. Pages: 1305-1316.e6
  5. Type of Article: Article
  6. ISSN: 1074-7613
  1. Abstract:

    Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with epithelial-cell cancers and B cell lymphomas. An effective EBV vaccine is not available. We found that antibodies to the EBV glycoprotein gH/gL complex were the principal components in human plasma that neutralized infection of epithelial cells and that antibodies to gH/gL and gp42 contributed to B cell neutralization. Immunization of mice and nonhuman primates with nanoparticle vaccines that displayed components of the viral-fusion machinery EBV gH/gL or gH/gL/gp42 elicited antibodies that potently neutralized both epithelial-cell and B cell infection. Immune serum from nonhuman primates inhibited EBV-glycoprotein-mediated fusion of epithelial cells and B cells and targeted an epitope critical for virus-cell fusion. Therefore, unlike the leading EBV gp350 vaccine candidate, which only protects B cells from infection, these EBV nanoparticle vaccines elicit antibodies that inhibit the virus-fusion apparatus and provide cell-type-independent protection from virus infection.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.immuni.2019.03.010
  3. PMID: 30979688
  4. View record in Web of Science®
  5. WOS: 000468429500019

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel